A large international genetic study led by Ole Andreassen at the University of Oslo and Oslo University Hospital has identified 127 regions in human DNA associated with the risk of developing Alzheimer's disease. Forty-eight of those regions had not previously been linked to the disease in this way. The research, published in Nature, analyzed genetic data from about 2.8 million people, including 183,620 people with Alzheimer's.
A central thread of the findings concerns microglia, the immune cells in the brain that clear away harmful substances and damaged cellular material. The researchers reported new genetic evidence related to how these cells are activated, how immune cells are recruited, and how material is cleared within the brain. The team also found genetic links to the processing of amyloid, the protein that can accumulate in the brain in Alzheimer's, as well as to nerve cell repair, the activation of astrocytes (supporting brain cells), and the maintenance of the insulating layer around nerve fibers.
The study also pointed beyond the immune system. For the first time, the researchers identified several specific types of neurons that show enrichment for genetic signal and may play a role in how the disease develops. Co-author Shahram Bahrami described the work as adding detail to what was already known about immune involvement, connecting specific genetic risk factors to more defined biological processes.
The team also revised an estimate of how much common genetic variation contributes to risk. Together these variants are estimated to explain about 16 percent of the differences in Alzheimer's risk between people, nearly three times an earlier estimate of around 5 percent. The researchers attribute much of the higher figure to a statistical method that better accounts for APOE, a gene with an unusually large effect on risk. Co-author Alexey Shadrin stressed that this is a population-level figure and does not mean a genetic test can determine whether an individual will develop the disease, since age, environment and other factors matter too.
The authorsframe the genetic associations as a starting point rather than proof that targeting any particular gene will produce a treatment. Follow-up work is needed to determine which associations play a causal role and whether intervening in those processes would be safe and meaningful. The study was conducted under the International Psychiatric Genomics Consortium, pooling data from 30 research groups, and the researchers emphasized the need for continued investment in large-scale genetics and for better representation of groups underrepresented in past studies.